By Katherine Hamilton

AnaptysBio plans to explore separating into two publicly traded companies.

The San Diego biotechnology company would split its business into a royalty management business and a biopharma business, it said Monday.

The royalty management company would hold and manage the rights to the royalties from some of its drugs, including Jamperli, a cancer treatment developed with GSK that had $262 million in sales during the second quarter, and imsidolimab, a psoriasis treatment developed with Vanda.

The royalty management company would require minimal staff and infrastructure, and would retain AnaptysBio's net operating loss carryforwards, AnaptysBio said.

The biopharma company would continue AnaptysBio's development for autoimmune and inflammatory disease treatments, including rosnilimab, ANB033 and ANB101. It would launch with enough capital to fund operations for at least two years.

AnaptysBio expects the separation of the biopharma would be completed by year-end 2026. Daniel Faga, AnaptysBio's chief executive and president, plans to become chief executive of the biopharma company at that time.

Both companies would operate under new names, AnaptysBio said.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

September 29, 2025 16:53 ET (20:53 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.